Graham Speight, Carolin Müller, James Reid, Lynne Edhouse, Jolyon Holdstock, Lyudmila Georgieva
The capture and molecular analysis of cell-free DNA (cfDNA) released from cells under certain pathological conditions, including cancer, provides a non-invasive alternative to currently used practices via use of liquid biopsy samples.
The rapid development of next-generation sequencing (NGS) technologies in recent years, has led to a significant reduction in sequencing cost with improved accuracy.
In liquid biopsy research, NGS can be applied to sequence circulating tumour DNA (ctDNA; DNA fragments released by tumour cells). As such, NGS could provide molecular characterisation of tumour-specific genomic alterations in ctDNA, allowing for non-invasive and real-time monitoring of disease development.
The aim of this study is to evaluate a modified version of the OGT™ Universal NGS Workflow Solution in conjunction with a custom SureSeq™ targeted panel for use with cfDNA.
Once you have registered with us for free you will be able to read all our supportive literature, video tutorials and webinars.